- Home
- EVF vs ZNTL Comparison
EVF vs ZNTL Comparison
Compare EVF & ZNTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EVF
- ZNTL
- Stock Information
- Founded
- EVF 1998
- ZNTL 2014
- Country
- EVF United States
- ZNTL United States
- Employees
- EVF N/A
- ZNTL N/A
- Industry
- EVF Investment Managers
- ZNTL Biotechnology: Pharmaceutical Preparations
- Sector
- EVF Finance
- ZNTL Health Care
- Exchange
- EVF Nasdaq
- ZNTL Nasdaq
- Market Cap
- EVF 101.0M
- ZNTL 105.8M
- IPO Year
- EVF N/A
- ZNTL 2020
- Fundamental
- Price
- EVF $5.51
- ZNTL $1.50
- Analyst Decision
- EVF
- ZNTL Buy
- Analyst Count
- EVF 0
- ZNTL 7
- Target Price
- EVF N/A
- ZNTL $8.46
- AVG Volume (30 Days)
- EVF 93.3K
- ZNTL 831.8K
- Earning Date
- EVF 01-01-0001
- ZNTL 11-11-2025
- Dividend Yield
- EVF 10.68%
- ZNTL N/A
- EPS Growth
- EVF N/A
- ZNTL N/A
- EPS
- EVF 0.94
- ZNTL N/A
- Revenue
- EVF N/A
- ZNTL $26,865,000.00
- Revenue This Year
- EVF N/A
- ZNTL N/A
- Revenue Next Year
- EVF N/A
- ZNTL N/A
- P/E Ratio
- EVF $6.74
- ZNTL N/A
- Revenue Growth
- EVF N/A
- ZNTL N/A
- 52 Week Low
- EVF $5.20
- ZNTL $1.01
- 52 Week High
- EVF $6.84
- ZNTL $5.44
- Technical
- Relative Strength Index (RSI)
- EVF 38.47
- ZNTL 43.42
- Support Level
- EVF $5.54
- ZNTL $1.60
- Resistance Level
- EVF $5.58
- ZNTL $2.02
- Average True Range (ATR)
- EVF 0.04
- ZNTL 0.13
- MACD
- EVF 0.00
- ZNTL -0.04
- Stochastic Oscillator
- EVF 35.40
- ZNTL 6.25
About EVF Eaton Vance Senior Income Trust
Eaton Vance Senior Income Trust is a United States-based diversified, closed-end management investment company. Its investment objective is to provide a high level of current income consistent with the preservation of capital, by investing in senior, secured floating-rate loans. The trust invests in below-investment-grade floating-rate loans, which are considered speculative because of the credit risk of their issuers. Its portfolio of investment consists of aerospace and defense, automotive, beverage, building and development, business equipment and services, cable and satellite television, and other areas.
About ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.